15965-56-7

Basic information

• Product Name: 1H-Benzimidazole,2,4-dichloro-(9CI)
• Synonyms: 1H-Benzimidazole,2,4-dichloro-(9CI);2,4-Dichloro-1H-benzo[d]iMidazole;2,4-DICHLORO-1H-BENZOIMIDAZOLE;2,4-dichloro-1H-Benzimidazole
• CAS NO: 15965-56-7
• Molecular Formula: C7H4Cl2N2
• Molecular Weight: 187.029
• EINECS: 278-914-6
• Product Categories: BENZIMIDAZOLE
• Mol File: 15965-56-7.mol

Chemical Properties

• Boiling Point: 273.2 °C at 760 mmHg
• Flash Point: 119 °C
• Appearance: /
• Density: 1.48 g/cm³
• PKA: 7.40±0.30(Predicted)
• CAS DataBase Reference: 1H-Benzimidazole,2,4-dichloro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole,2,4-dichloro-(9CI)(15965-56-7)
• EPA Substance Registry System: 1H-Benzimidazole,2,4-dichloro-(9CI)(15965-56-7)

Safety Data

• Hazardous Substances Data: 15965-56-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Benzimidazole,2,4-dichloro-(9CI) is used as a building block for the synthesis of various pharmaceuticals. Its unique structure and properties make it a valuable component in the development of new drugs with diverse therapeutic applications.
Used in Agrochemical Industry:
1H-Benzimidazole,2,4-dichloro-(9CI) is also used as a building block for the synthesis of pesticides. Its chemical properties allow it to be incorporated into compounds that can effectively control and manage pests in agricultural settings.
Used in Antimicrobial Applications:
1H-Benzimidazole,2,4-dichloro-(9CI) has been studied for its potential antimicrobial properties. It may be utilized in the development of new antimicrobial agents to combat resistant bacteria and other microorganisms.
Used in Antiviral Applications:
Additionally, 1H-Benzimidazole,2,4-dichloro-(9CI) has shown potential antiviral properties. This makes it a candidate for further research and development as a component in antiviral medications to treat various viral infections.

Upstream product

• 59483-54-4 3-chloro-2-nitro-aniline 
• 21745-41-5 2,3-diaminochlorobenzene 
• 5918-97-8 4-chloro-1,3-dihydro-2H-benzoimidazol-2-one 

Relevant articles and documents

INHIBITORS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE

A compound of formula I, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: Formula I wherein X1 is benzimidazolyl, substituted benzimidazolyl, azabenzimidazolyl, substituted azabenzimidazolyl, pyrazolyl, or substituted pyrazolyl; X2 is aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkyl, substituted cycloalkyl, (cycloalkyl)alkyl, substituted (cycloalkyl)alkyl, heterocycloalkyl, substituted heterocycloalkyl, (heterocycloalkyl)alkyl, substituted (heterocycloalkyl)alkyl, alkyl, substituted alkyl, alkoxycarbonyl, substituted alkoxycarbonyl, dialkylaminocarbonyl, substituted dialkylaminocarbonyl, (heterocycloalkyl)carbonyl, or substituted (heterocycloalkyl)carbonyl; X3 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, heterocycloalkyl, substituted heterocycloalkyl, (heterocycloalkyl)alkyl, substituted (heterocycloalkyl)alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkyl, substituted cycloalkyl, (cycloalkyl)alkyl, or substituted (cycloalkyl)alkyl; and X4 is hydroxy, amino, alkyl, or hydrogen.

BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS

The present invention is directed to benzoimidazole compounds of the formula (1) and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and met

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright